Biolog
Biolog provides cell-based phenotyping technologies and assays that enable researchers to characterize microbial and mammalian cells through their metabolic and biochemical activity profiles. The company's phenotype microarray technology allows high-throughput screening of cellular responses to thousands of chemical compounds and environmental conditions simultaneously, generating comprehensive phenotypic…
Funding snapshot
About
Biolog provides cell-based phenotyping technologies and assays that enable researchers to characterize microbial and mammalian cells through their metabolic and biochemical activity profiles. The company's phenotype microarray technology allows high-throughput screening of cellular responses to thousands of chemical compounds and environmental conditions simultaneously, generating comprehensive phenotypic fingerprints that reveal metabolic pathways, drug resistance mechanisms, and cellular function. Biolog's assays are used across pharmaceutical development, agricultural biotechnology, environmental microbiology, and academic research, supporting applications including antimicrobial susceptibility testing, cell line characterization, microbial identification, and functional genomics. The company's platform differentiates itself through its ability to measure live cell responses in real-time across hundreds of conditions in a single experiment, providing functional data that complements genomic and proteomic analysis. Founded in 1984 and headquartered in Hayward, California, Biolog has raised approximately $33.6 million in a Series A round backed by Broadoak Capital Partners, RCT, Redfund Capital, and HHS.
Business model
Genomics > Enabling Technologies > Instrument Systems > Single Cell Genomics,
Life Sciences Platforms and Tools > Instruments > Cell Biology > Cell Analysis
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.